- Home
- EDTK vs MEIP Comparison
EDTK vs MEIP Comparison
Compare EDTK & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- MEIP
- Stock Information
- Founded
- EDTK 2013
- MEIP 2000
- Country
- EDTK China
- MEIP United States
- Employees
- EDTK N/A
- MEIP N/A
- Industry
- EDTK Other Consumer Services
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- MEIP Health Care
- Exchange
- EDTK Nasdaq
- MEIP Nasdaq
- Market Cap
- EDTK 15.7M
- MEIP 17.1M
- IPO Year
- EDTK 2020
- MEIP 2003
- Fundamental
- Price
- EDTK $1.04
- MEIP $1.98
- Analyst Decision
- EDTK
- MEIP Hold
- Analyst Count
- EDTK 0
- MEIP 1
- Target Price
- EDTK N/A
- MEIP N/A
- AVG Volume (30 Days)
- EDTK 6.0K
- MEIP 11.6K
- Earning Date
- EDTK 05-02-2025
- MEIP 05-08-2025
- Dividend Yield
- EDTK N/A
- MEIP N/A
- EPS Growth
- EDTK N/A
- MEIP N/A
- EPS
- EDTK N/A
- MEIP N/A
- Revenue
- EDTK $624,365.00
- MEIP N/A
- Revenue This Year
- EDTK N/A
- MEIP N/A
- Revenue Next Year
- EDTK N/A
- MEIP N/A
- P/E Ratio
- EDTK N/A
- MEIP N/A
- Revenue Growth
- EDTK N/A
- MEIP 33.76
- 52 Week Low
- EDTK $0.84
- MEIP $1.46
- 52 Week High
- EDTK $1.27
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- EDTK 57.61
- MEIP 40.20
- Support Level
- EDTK $0.94
- MEIP $1.86
- Resistance Level
- EDTK $1.06
- MEIP $2.35
- Average True Range (ATR)
- EDTK 0.05
- MEIP 0.16
- MACD
- EDTK 0.00
- MEIP 0.02
- Stochastic Oscillator
- EDTK 74.19
- MEIP 68.42
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.